 CAMBRIDGE, Mass., Aug. 23, 2022 GLOBE NEWSWIRE -- Intellia Therapeutics, Inc. NASDAQ:NTLA, a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, today announced that an abstract featuring interim clinical data from the Phase 12 study of NTLA-2002 has been selected for an oral presentation at the 2022 Bradykinin Symposium, taking place September 15-16 in Berlin, Germany. NTLA-2002 is an investigational in vivo CRISPRCas9 therapy in development as a single-dose treatment to prevent angioedema attacks in people living with hereditary angioedema HAE. The presentation will include interim safety, kallikrein reduction and attack rate data from the ongoing dose-escalation portion of Intellias first-in-human study of NTLA-2002. 